secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-08-12T20:16:29+00:00
Accession:  0001104659-26-094896
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata posts Q2 net income $74.1M on non-cash gain; AP-SA02 Phase 3 on track
----------------------------------------------------------------------------

- Q2 2026 net income $74.1M vs net loss $16.3M in 2025; basic EPS $2.02, diluted loss $0.27.
- Operating loss $10.3M vs $6.8M; R&D $7.6M, G&A $5.2M; grant revenue $2.5M.
- Received $2.5M additional DoW funding, total $28.7M; cash $24.0M vs $8.7M at end-2025.
- FDA granted Fast Track designation for AP-SA02; Phase 3 protocol submitted; Agreed iPSP obtained.
- Promoted David House to CFO; appointed Daniel B. Gilmer, Ph.D. to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/0001104659-26-094896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer